Literature DB >> 20876319

Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.

Kolitha Basnayake1, Chee Kay Cheung, Michael Sheaff, William Fuggle, Dia Kamel, Sandra Nakoinz, Colin A Hutchison, Mark Cook, John Stoves, Arthur R Bradwell, Paul Cockwell.   

Abstract

BACKGROUND: Most cases of dialysis-dependent acute kidney injury due to myeloma cast nephropathy do not recover renal function. Renal biopsy typically shows cast formation, direct tubular injury and interstitial inflammation caused by nephrotoxic monoclonal free light chains (FLC). Established scarring at presentation is rarely severe. There is little data on in situ evolution of renal injury. AIMS: To conduct a detailed histological study of four patients with cast nephropathy.
METHODS: Cast nephropathy was confirmed by renal biopsy. Treatment consisted of chemotherapy and high cut-off dialysis to maximise extracorporeal removal of FLC and reduce renal toxicity. All four patients remained dialysis dependent at 6 weeks, at which time they underwent a further biopsy.
RESULTS: Three patients achieved independence from dialysis. Six-week biopsies showed differential changes in chronic damage from no progression, to accelerated progression of scarring from 10% to 42%, despite a rapid and sustained fall in FLC in all patients. In three patients there was a major reduction in intratubular cast numbers; these patients subsequently recovered renal function. In one patient who continued to have high cast formation at 6 weeks there was no subsequent renal recovery.
CONCLUSIONS: Some FLC clones can promote rapid renal scarring. Significant reductions in cast formation on repeat biopsy may identify the potential for late renal recovery. Early diagnosis and treatment may prove crucial in determining renal recovery. Patients who have not recovered renal function after a period of treatment may be usefully reassessed by repeat biopsy for quantitative analysis of chronic damage and cast numbers.

Entities:  

Mesh:

Year:  2010        PMID: 20876319     DOI: 10.1136/jcp.2010.079236

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

Review 2.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 3.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

Review 4.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

5.  Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy.

Authors:  Sumit Grover; Pavneet Kaur Selhi; Neena Sood; Jasvinder Singh Sandhu; Harpreet Kaur
Journal:  J Clin Diagn Res       Date:  2016-06-01

6.  Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial.

Authors:  Ritika Rana; Paul Cockwell; Mark Drayson; Mark Cook; Guy Pratt; David A Cairns; Charlotte Pawlyn; Graham Jackson; Faith Davies; Gareth Morgan; Jennifer Helen Pinney
Journal:  Blood Adv       Date:  2020-11-24

7.  Treatment of multiple myeloma with renal involvement: the nephrologist's view.

Authors:  Alexandre Favà; Xavier Fulladosa; Nuria Montero; Juliana Draibe; Joan Torras; Montse Gomà; Josep M Cruzado
Journal:  Clin Kidney J       Date:  2018-08-01

8.  Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.

Authors:  Punit Yadav; Insara Jaffer Sathick; Nelson Leung; Elizabeth E Brown; Mark Cook; Paul W Sanders; Paul Cockwell
Journal:  Blood Cancer J       Date:  2020-03-03       Impact factor: 11.037

Review 9.  Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management.

Authors:  Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela V Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-25

10.  Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report.

Authors:  Ritika Rana; Guy Pratt; Mark Cook; Mark Trehane Drayson; Karthik Ramasamy; Ross Sadler; Doreen Zhu; Thomas Connor; Jennifer Helen Pinney
Journal:  BMJ Open Qual       Date:  2021-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.